Business-to-business accounts payable spending in midsize cities has significantly outpaced larger cities. Here's why.

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

CI&T Inc.'s strong flow adoption and co-creation with top clients fuel revenue growth. Click here to read an analysis of CINT ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

India's real estate revival has gained momentum, with large developers experiencing strong pre-sales, rising cash flows, and ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.